Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 2, 2006, Pages 459-465

  Rades, Dirk ^a   Tribius, Silke ^a   Yekebas, Emre F ^a   Bahrehmand, Roia ^a,b   Wildfang, Ingeborg ^c   Kilic, Ergin ^a   Muellerleile, Ulrich ^d   Gross, Eberhard ^d   Schild, Steven E ^e   Alberti, Winfried ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c Siloah Hospital   (Germany)

^d ASKLEPIOS HOSPITAL BARMBEK   (Germany)

^e MAYO CLINIC   (United States)

Author keywords

Chemoradiation; Epoetin alfa; Esophageal cancer; Locoregional control; Survival

Indexed keywords

CHEMOTHERAPY; HEMOGLOBIN; PATIENT MONITORING; RADIOTHERAPY;

CHEMORADIATION; EPOETIN ALFA; ESOPHAGEAL CANCER; LOCOREGIONAL CONTROL; SURVIVAL;

TUMORS;

CISPLATIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGUS CANCER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; MALE; OBSERVATIONAL STUDY; OXYGENATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEX RATIO; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPOETIN ALFA; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE;

EID: 33646245915     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.12.019     Document Type: Article

References (40)

1. Daly J.M., Fry W.A., Little A.G., et al. Esophageal cancer. Results of an American College of Surgeons patient care evaluation study. J Am Coll Surg 190 (2000) 562-573
2. Eloubeidi M.A., Desmond R., Arguedas M.R., et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S. The importance of tumor length and lymph node status. Cancer 95 (2002) 1434-1443
3. Polee M.B., Hop W.C.J., Kok T.C., et al. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89 (2003) 2045-2050
4. Kodaira T., Fuwa N., Itoh Y., et al. Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol 26 (2003) 392-397
5. Richmond J., Seydel H.G., Bae Y., et al. Comparison of three treatment strategies for esophageal cancer within a single institution. Int J Radiat Oncol Biol Phys 13 (1987) 1617-1620
6. Jeremic B., Shibamoto Y., Acimovic L., et al. Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus. a phase II study. Int J Radiat Oncol Biol Phys 40 (1998) 1061-1066
7. Rades D., Schild S.E., Bahrehmand R., et al. Prognostic factors in the treatment of esophageal cancer with radiotherapy or radiochemotherapy. The importance of pre-treatment hemoglobin levels. Cancer 103 (2005) 1740-1746
8. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
9. Munstedt K., Volzing M., and Von Georgi R. Hemoglobin levels during radiotherapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep 11 (2004) 711-717
10. Vaupel P., Thews O., and Hockel M. Treatment resistance of solid tumors. Role of hypoxia and anemia. Med Oncol 18 (2001) 243-259
11. Overgaard J., Sand Hansen H., Lindelov B., et al. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 20 Suppl 1 (1991) 143-149
12. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 46 (1998) 344-346
13. Vaupel P., Thews O., Mayer A., et al. Oxygenation status of gynecologic tumors. What is the optimal hemoglobin level?. Strahlenther Onkol 178 (2002) 727-731
14. Harrison L.B., Shasha D., and Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy. Prognostic significance and treatment. Oncology 63 Suppl. 2 (2002) 11-18
15. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50 (2001) 705-715
16. Blohmer J.U., Wurschmidt F., Petry U., et al. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer (Abstr.). Proc Am Soc Clin Oncol 22 (2003) 447
17. Antonadou D., Cardamakis E., Sarris G., et al. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy (Abstr.). Radiother Oncol 48 Suppl. 1 (1998) S122
18. Rades D., Schild S.E., Yekebas E.F., et al. Epoetin alfa during radiotherapy for stage III esophageal carcinoma. Cancer 103 (2005) 2274-2279
19. Baz R., Brand B., McGowan E., et al. High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma. J Clin Oncol 23 Suppl (2005) 6621
20. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy. Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
21. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
22. Lavey R.S., and Dempsey W.H. Erythropoietin increases hemoglobin in cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys 27 (1993) 1147-1152
23. Dusenbery K.E., McGuie W.A., Holt P.J., et al. Erythropoietin increases hemoglobin during radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 29 (1994) 1079-1080
24. Sweeney P.J., Nicolae D., Ignacio I., et al. Effect of subcutaneous recombinant erythropoietin in cancer patients receiving radiotherapy. Final report of a randomized, open-labeled phase II trial. Br J Cancer 77 (1998) 1996-2002
25. Westphal G., Niederberger L., Blum C., et al. Erythropoietin and G-CSF receptors in human tumor cells. Expression and aspects regarding functionality. Tumori 88 (2002) 150-159
26. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 (2000) 647-657
27. Selzer E., Wachek V., Kodym R., et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 179 (2000) 527-534
28. Acs G., Zhang P.J., McGrath C.M., et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162 (2003) 1789-1806
29. Batra S., Perelman N., Luck L.R., et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83 (2003) 1477-1487
30. Stuben G., Thews O., Pottgen C., et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127 (2001) 346-350
31. Thews O., Kelleher D.K., and Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61 (2001) 1358-1361
32. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
33. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow up of a prospective randomized trial. JAMA 281 (1999) 1623-1627
34. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
35. Wong R., Malthaner R.A., Zuraw L., et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus. A practice guideline. Int J Radiat Oncol Biol Phys 55 (2003) 930-942
36. Coia L.R., Minsky B.D., Berkey B.A., et al. Outcome of patients receiving radiation for cancer of the oesophagus. Results of the 1992-1994 patterns of care study. J Clin Oncol 18 (2000) 455-462
37. Dellinger E.P., and Anaya D.A. Infectious and immunological consequences of blood transfusions. Crit Care 8 Suppl. 2 (2004) S18-S23
38. Bush R.S. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12 (1986) 2047-2050
39. Kapp K.S., Poschauko J., Geyer E., et al. Evaluation of the effect of routine packed blood cell transfusions in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 58-66
40. Dunst J. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?. Strahlenther Onkol 180 (2004) 671-681